Reasons for cancer metastasis: A holistic perspective (Review)

Wang,Rui‑An; Lu,You‑Yong; Fan,Dai‑Ming

doi:10.3892/mco.2015.623

Reasons for cancer metastasis: A holistic perspective (Review)

Authors:
- Rui‑An Wang
- You‑Yong Lu
- Dai‑Ming Fan
View Affiliations

Affiliations: State Key Laboratory of Cancer Biology, The Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China, Laboratory of Molecular Oncology, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China
Published online on: August 14, 2015 https://doi.org/10.3892/mco.2015.623
Pages: 1199-1202

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Over several years, scientists investigating cancer have focused their efforts on elucidating the mechanisms underlying cancer metastasis, with the aim of finding a way to inhibit this process. These mechanisms, however, only explain the process of cancer metastasis, but do not explain why cancer would metastasize in the first place. cancer metastasizes due to several factors, namely attack by the immune system, lack of oxygen and necessary nutrients, large amounts of lactic acid produced by glycolysis and increased cell death. Therefore, the majority of the presently available treatments for cancer also bear the potential to induce metastasis. Thus, it is crucial in medical practice to minimize the risk of cancer metastasis during a time when there are no effective means to inhibit this process.

View Figures

View References

1	Vaux DL: In defense of the somatic mutation theory of cancer. Bioessays. 33:341–343. 2011. View Article : Google Scholar : PubMed/NCBI
2	Sonnenschein C and Soto AM: Somatic mutation theory of carcinogenesis: Why it should be dropped and replaced. Mol Carcinog. 29:205–211. 2000. View Article : Google Scholar : PubMed/NCBI
3	Soto AM and Sonnenschein C: The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. Bioessays. 33:332–340. 2011. View Article : Google Scholar : PubMed/NCBI
4	Duesberg P and Rasnick D: Aneuploidy, the somatic mutation that makes cancer a species of its own. Cell Motil Cytoskeleton. 47:81–107. 2000. View Article : Google Scholar : PubMed/NCBI
5	Zhang LJ, Li H, Zhang LY, et al: Metastasis: inherent vs acquired phenotype. Med Hypotheses. 74:874–876. 2010. View Article : Google Scholar : PubMed/NCBI
6	Weinberg RA: Mechanisms of malignant progression. Carcinogenesis. 29:1092–1095. 2008. View Article : Google Scholar : PubMed/NCBI
7	Tarin D, Thompson EW and Newgreen DF: The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res. 65:59962005. View Article : Google Scholar : PubMed/NCBI
8	Suzuki M and Tarin D: Gene expression profiling of human lymph node metastases and matched primary breast carcinomas: clinical implications. Mol Oncol. 1:172–180. 2007. View Article : Google Scholar : PubMed/NCBI
9	Weinberg RA: Is metastasis predetermined? Mol Oncol. 1:263–264, 265–266. 2007. View Article : Google Scholar : PubMed/NCBI
10	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
11	Lipponen P, Aaltomaa S, Kosma VM and Syrjanen K: Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 30A. 2068–2073. 1994. View Article : Google Scholar
12	Lipponen PK and Aaltomaa S: Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol. 173:333–339. 1994. View Article : Google Scholar : PubMed/NCBI
13	Lipponen P: Apoptosis in breast cancer: relationship with other pathological parameters. Endocr Relat Cancer. 6:13–16. 1999. View Article : Google Scholar : PubMed/NCBI
14	Nishimura R, Nagao K, Miyayama H, et al: Apoptosis in breast cancer and its relationship to clinicopathological characteristics and prognosis. J Surg Oncol. 71:226–234. 1999. View Article : Google Scholar : PubMed/NCBI
15	Sinicrope FA, Hart J, Hsu HA, Lemoine M, Michelassi F and Stephens LC: Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. Clin Cancer Res. 5:1793–1804. 1999.PubMed/NCBI
16	Lee KH, Im SA, Oh DY, et al: Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer. 7:632007. View Article : Google Scholar : PubMed/NCBI
17	Ali HR, Dawson SJ, Blows FM, et al: A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol. 226:97–107. 2012. View Article : Google Scholar : PubMed/NCBI
18	Callagy GM, Pharoah PD, Pinder SE, et al: Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham prognostic index. Clin Cancer Res. 12:2468–2475. 2006. View Article : Google Scholar : PubMed/NCBI
19	Callagy GM, Webber MJ, Pharoah PD and Caldas C: Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. Bmc Cancer. 8:1532008. View Article : Google Scholar : PubMed/NCBI
20	Rolland P, Spendlove I, Madjd Z, et al: The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. Int J Cancer. 120:1311–1317. 2007. View Article : Google Scholar : PubMed/NCBI
21	Poincloux L, Durando X, Seitz JF, et al: Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer. Surg Oncol. 18:357–365. 2009. View Article : Google Scholar : PubMed/NCBI
22	Sinicrope FA, Hart J, Michelassi F and Lee JJ: Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res. 1:1103–1110. 1995.PubMed/NCBI
23	Tomita M, Matsuzaki Y, Edagawa M, Shimizu T, Hara M and Onitsuka T: Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer. Eur J Surg Oncol. 29:654–657. 2003. View Article : Google Scholar : PubMed/NCBI
24	MacherGoeppinger S, Bermejo JL, Wagener N, et al: Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas. Cancer Lett. 301:203–211. 2011. View Article : Google Scholar : PubMed/NCBI
25	Ugurel S, Rappl G, Tilgen W and Reinhold U: Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res. 7:1282–1286. 2001.PubMed/NCBI
26	Partridge L, Gems D and Withers DJ: Sex and death: what is the connection? Cell. 120:461–472. 2005. View Article : Google Scholar : PubMed/NCBI
27	Knowlton K, Mancini M, Creason S, Morales C, Hockenbery D and Anderson BO: Bcl-2 slows in vitro breast cancer growth despite its antiapoptotic effect. J Surg Res. 76:22–26. 1998. View Article : Google Scholar : PubMed/NCBI
28	Pietenpol JA, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW and Vogelstein B: Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res. 54:3714–3717. 1994.PubMed/NCBI
29	O'Reilly LA, Huang DC and Strasser A: The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. Embo J. 15:6979–6990. 1996.PubMed/NCBI
30	Chen L, Park SM, Tumanov AV, et al: CD95 promotes tumour growth. Nature. 465:492–496. 2010. View Article : Google Scholar : PubMed/NCBI
31	Huang Q, Li F, Liu X, et al: Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med. 17:860–866. 2011. View Article : Google Scholar : PubMed/NCBI
32	Hui L, Zatloukal K, Scheuch H, Stepniak E and Wagner EF: Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest. 118:3943–3953. 2008. View Article : Google Scholar : PubMed/NCBI
33	Yang C, Davis JL, Zeng R, et al: Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation. Cancer Discov. 3:212–223. 2013. View Article : Google Scholar : PubMed/NCBI
34	Lippitz BE: Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 14:e218–e228. 2013. View Article : Google Scholar : PubMed/NCBI
35	Wang RA, Li QL, Li ZS, et al: Apoptosis drives cancer cells proliferate and metastasize. J Cell Mol Med. 17:205–211. 2013. View Article : Google Scholar : PubMed/NCBI
36	Fidler IJ: Macrophages and metastasis - a biological approach to cancer therapy. Cancer Res. 45:4714–4726. 1985.PubMed/NCBI
37	Prehn RT and Prehn LM: Cancer immunotherapy by immunosuppression. Theor Biol Med Model. 7:452010. View Article : Google Scholar : PubMed/NCBI
38	Thompson CB: Rethinking the regulation of cellular metabolism. Cold Spring Harb Symp Quant Biol. 76:23–29. 2011. View Article : Google Scholar : PubMed/NCBI
39	Bonuccelli G, Tsirigos A, WhitakerMenezes D, et al: Ketones and lactate ‘fuel’ tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle. 9:3506–3514. 2010. View Article : Google Scholar : PubMed/NCBI
40	Estrella V, Chen T, Lloyd M, et al: Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 73:1524–1535. 2013. View Article : Google Scholar : PubMed/NCBI
41	Ibrahim HA, Cornnell HH, Coelho RML, et al: Reduction of metastasis using a non-volatile buffer. Clin Exp Metastasis. 28:841–849. 2011. View Article : Google Scholar : PubMed/NCBI
42	Ebos JM, Lee CR, CruzMunoz W, Bjarnason GA, Christensen JG and Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15:232–239. 2009. View Article : Google Scholar : PubMed/NCBI
43	PaezRibes M, Allen E, Hudock J, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 15:220–231. 2009. View Article : Google Scholar : PubMed/NCBI
44	Zhu XD, Sun HC, Xu HX, et al: Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models. Angiogenesis. 16:809–820. 2013. View Article : Google Scholar : PubMed/NCBI
45	Wang WQ, Liu L, Sun HC, et al: Tanshinone IIA inhibits metastasis after palliative resection of hepatocellular carcinoma and prolongs survival in part via vascular normalization. J Hematol Oncol. 5:692012. View Article : Google Scholar : PubMed/NCBI